4546-55-8

Basic information

• Product Name: N-BENZOYLADENOSINE
• Synonyms: N6-Benzoyladenosine≥ 99.9% (HPLC);N6-BENZOYLADENOSINE;N6-BENZOYL-D-ADENOSINE;N-BENZOYLADENOSINE;N4-Benzoyl;N(sup 6)benzoyladenosine;N6-Bz-rA;Bz-rA
• CAS NO: 4546-55-8
• Molecular Formula: C₁₇H₁₇N₅O₅
• Molecular Weight: 371.35
• EINECS: 2017-001-1
• Product Categories: Biochemistry;Nucleosides and their analogs;Nucleosides, Nucleotides & Related Reagents;Nucleosides;Oligonucleotide Synthesis;Specialty Synthesis
• Mol File: 4546-55-8.mol
• Article Data: 24

Chemical Properties

• Melting Point: 141-145 °C(lit.)
• Appearance: /
• Density: 1.70
• Refractive Index: -48 ° (C=1, DMSO)
• Storage Temp.: Store at 0°C
• PKA: 7.87±0.43(Predicted)
• BRN: 632501
• CAS DataBase Reference: N-BENZOYLADENOSINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BENZOYLADENOSINE(4546-55-8)
• EPA Substance Registry System: N-BENZOYLADENOSINE(4546-55-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 24/25
• Hazardous Substances Data: 4546-55-8(Hazardous Substances Data)

Usage

Chemical Properties

Solid

Uses

N6-Benzoyladenosine is an anti tumor agent.

InChI:InChI=1/C17H17N5O5/c23-6-10-12(24)13(25)17(27-10)22-8-20-11-14(18-7-19-15(11)22)21-16(26)9-4-2-1-3-5-9/h1-5,7-8,10,12-13,17,23-25H,6H2,(H,18,19,21,26)/t10-,12-,13-,17-/m1/s1

Upstream product

• 62374-23-6 N⁶,N⁶,2',3',5'-pentabenzoyl-β-D-adenosine 
• 65-85-0 benzoic acid 
• 93-58-3 benzoic acid methyl ester 
• 58-61-7 adenosine 
• 6984-53-8 N⁶,2',3',5'-tetra-O-benzoyladenosine 
• 93-97-0 benzoic acid anhydride 
• 1348775-39-2 adenosine 
• 98-88-4 benzoyl chloride 
• 79154-57-7 3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-N₆-benzoyladenosine 
• 1314034-32-6 N₆-benzoyl-3',5'-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2'-O-(methoxymethyl)adenosine 
• 105014-93-5 (2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-(3,4-dimethoxy-benzyloxy)-2-hydroxymethyl-tetrahydro-furan-3-ol 
• 80015-54-9 (2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)- 2-(hydroxymethyl)-4-((4-methoxybenzyl)oxy)tetrahydrofuran-3-ol 
• 184229-60-5 Acetic acid (2R,3R,4R,5R)-2-(6-benzoylamino-purin-9-yl)-4-benzyloxy-5-((R)-1,2-diacetoxy-ethyl)-tetrahydro-furan-3-yl ester 
• 184229-61-6 N-{9-[(2R,3R,4S,5R)-4-Benzyloxy-5-((R)-1,2-dihydroxy-ethyl)-3-hydroxy-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide 

Downstream Products

• 88121-45-3 6-N-benzoyl-3',5'-bis-O-tert-butyldimethylsilyladenosine 
• 86529-09-1 N-(9-((2R,3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-(((tertbutyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 10280-24-7 6-N-benzoyl-9-(2,3-O-ethoxymethylidene-β-D-ribofuranosyl)adenine 
• 81691-32-9 N⁶-benzoyl-2',5'-bis-O-(tert-butyldimethylsilyl)adenosine 
• 1006062-18-5 9-[2-deoxy-5-O-(4,4'-dimethoxytrityl)-2-methoxalylamino-β-D-arabinofuranosyl]-N⁶-benzoyladenine 
• 69293-36-3 N⁶-benzoyl-9-(2',3'-di-O-acetyl-β-D-ribofuranosyl)adenine 
• 136923-03-0 Trifluoro-methanesulfonic acid (2R,3R,3aR,9aR)-2-(6-benzoylamino-purin-9-yl)-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-3-yl ester 
• 201225-43-6 N-[9-((2R,3S,3aS,9aR)-3-Azido-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl)-9H-purin-6-yl]-benzamide 
• 201225-46-9 9-[2-amino-2-deoxy-5-O-(4,4'-dimethoxytrityl)-β-D-arabinofuranosyl]-N⁶-benzoyladenine 
• 201664-43-9 2',3'-di-O-acetyl-N⁶-benzoyl-5'-O-[(tert-butyl)diphenylsilyl]adenosine 
• 931386-09-3 N⁴-benzoyl-2'-O-(tert-butyldithiomethyl)cytidine 
• 913645-80-4 N⁶-benzoyl-2'-O-(tert-butyldithiomethyl)adenosine 
• 913645-81-5 N⁶-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(tert-butyldithiomethyl)adenosine 
• 913645-82-6 N⁶-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(tert-butyldithiomethyl)adenosine 3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) 

Relevant articles and documents

Method for preparing N6-benzoyladenosine

The invention discloses a method for preparing N6-benzoyladenosine. The method comprises the following steps: (1) weighing and adding adenosine and a protectant in a flask, adding a solvent and a catalyst, carrying out stirring refluxing for a period of t

CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE

Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.

COMPOUNDS

Disclosed herein are 2'-spiro-nucleosides of formula I and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus. Formula (I), where z is a four-or five-membered ring selected from among radicals a-o represented b